Show Summary Details
Page of

Unique Challenges Facing Immunotherapy of Metastatic Ovarian Cancer 

Unique Challenges Facing Immunotherapy of Metastatic Ovarian Cancer
Unique Challenges Facing Immunotherapy of Metastatic Ovarian Cancer

Michelle N. Messmer

, Colleen S. Netherby

, and Scott I. Abrams

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 11 July 2020

The immune system serves as an integral checkpoint to developing malignancies. However, when cancer ultimately becomes detectable, this implicates an inherent failure of effective immune control. One constant theme in cancer biology has been the ability of these “diseases,” in particular, ovarian cancer, to compromise immune-mediated mechanisms of neoplastic control. These empirical observations have subsequently laid the scientific foundation to investigate ways in which the immune system can be reengaged as a powerful therapeutic weapon, singly or in combination with other modalities. This field has been coined “cancer immunotherapy” and, importantly, strong progress has been made to date to justify its feasibility and potential merit. This chapter focuses on the fundamental immunologic principles that have guided the development of the cancer immunotherapy concept, as well as details both the successes and the limitations of cancer immunotherapy in patients with metastatic ovarian cancer.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.